Pd-1 signal inhibitor combination therapy
AssigneeKyoto University
InventorsTasuku Honjo, Kenji CHAMOTO, Sidonia FAGARASAN
Life of this patent
Estimating the term…
Abstract
A novel therapeutic strategy for the anti-PD-1 antibody therapy is provided. A pharmaceutical composition which comprises at least one substance selected from the group consisting of the following (i) to (iii) and is administered before, after or simultaneously with the administration of a PD-1 signal inhibitor: (i) ROS generators and substances that regulate downstream signaling pathways thereof, (ii) substances exhibiting an uncoupling effect and substances that regulate downstream signaling pathways thereof, and (iii) amino acids.
Claims10
A method of treating cancer, infection or a combination thereof in a subject in need thereof, comprising administering to the subject:
- (a) a substance that regulates PGC-1α/transcription factor complex;
- and
- (b) a PD-1 signaling inhibitor.
Dependencies are inferred from the claim text.